Heart Valve Devices Market by Product Type, Treatment, End User, and Region – Global Market Size Estimation, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2032
Overview
The Heart Valve Devices Market size was valued at USD 11.87 Billion in 2025 and the total Heart Valve Devices Market revenue is expected to grow at a CAGR of 11.2% from 2026 to 2032, reaching nearly USD 24.95 Billion by 2032.
Heart Valve Devices Market Overview
A heart valve device is a medical device that can replace or repair a damaged heart valve. The heart valve devices market encompasses developing, producing, and distributing medical devices used to repair or replace heart valves, essential for treating conditions like aortic stenosis and mitral regurgitation. These devices include transcatheter aortic valve replacements (TAVR), surgical heart valves, and mitral valve repair systems, widely available across hospitals, cardiac centres, and specialized clinics. This market includes various types of valves such as mechanical, biological, and transcatheter valves, each designed to meet specific patient needs. The increasing prevalence of heart valve disease, especially among the ageing population, has increased the demand for heart valve devices. Advances in technology, especially in minimally invasive procedures such as transcatheter aortic valve replacement (TAVR), have significantly driven rapid market growth, making these devices more accessible and widely used.
Regionally, North America, particularly the United States, dominates the heart valve devices market, driven by the high volume of procedures and rapid adoption of new technologies. Established companies like Edwards Lifesciences, Medtronic, and Boston Scientific have the resources to invest in research, development, and manufacturing infrastructure, allowing them to innovate and expand their product offerings. For instance, in May 2024, Edwards Lifesciences launched the SAPIEN 3 Ultra RESILIA valve in Europe, featuring advanced RESILIA tissue technology designed to improve durability. Similarly, Boston Scientific's ACURATE Prime Aortic Valve System, which received CE Mark approval in August 2024, demonstrates the company’s commitment to enhancing device performance and expanding treatment options.
To know about the Research Methodology :- Request Free Sample Report
Heart Valve Devices Market Dynamics
Increasing Transcatheter Aortic Valve Replacement (TAVR) Procedure Drives Heart Valve Devices Market Growth
The rise in minimally invasive procedures, particularly transcatheter aortic valve replacement (TAVR), is significantly driving the growth of the heart valve devices market. TAVR allows doctors to replace a diseased aortic valve without the need for traditional open-heart surgery. Instead of making a large incision in the chest, surgeons access the heart through a small catheter inserted in the groin or chest. This method reduces the risk of complications, shortens recovery time, and often leads to faster hospital discharges. For instance, in the United States, the number of TAVR procedures has increased dramatically, with more than 80,000 TAVR procedures performed annually in 2023, reflecting its growing acceptance among patients and healthcare providers.
The popularity of TAVR is tremendous among the elderly and high-risk patients who may not be suitable candidates for open heart surgery due to their age or other health conditions. The less invasive nature of the procedure means these patients have fewer complications and recover more quickly, making it a preferred option for many. The growing demand for TAVI/TAVR is contributing to the overall growth of the heart valve devices market as more healthcare systems adopt these advanced technologies. As a result, manufacturers invest in research and development to innovate and improve TAVI/TAVR devices, thus further driving market expansion.
• TAVR procedures have a 30-day mortality rate of approximately 2-3%, compared to 5-8% for traditional open-heart surgeries.
The High Costs of Manufacturing Heart Valve Devices
The high manufacturing cost of heart valve devices poses a major challenge in the heart valve devices market. These devices require advanced materials, sophisticated manufacturing processes and high-quality control to ensure they meet the highest standards of safety and efficacy. For example, many heart valves are made of materials such as titanium or specialized polymers, which are expensive. In addition, the precision required to manufacture these devices to match the precise specifications required for each patient is high, leading to increased labour and technology costs. In addition, these devices have to undergo extensive tests and clinical trials before being approved for use, increasing the total costs. All of these factors contribute to the high cost of manufacturing heart valve devices, making them expensive for both manufacturers and patients.
For emerging players, these high production costs can be difficult. Unlike established companies that have more resources, new entrants often find it difficult to absorb these costs. The need for large investments in research, development and manufacturing infrastructure can be a major barrier to entry. As a result, new entrants may find it difficult to scale their operations or offer their products at competitive prices, reducing their ability to gain market share.
Heart Valve Devices Market Segment Analysis
Based On Product Type, the Heart Valve Devices Market is segmented into Mechanical Heart Valves, Biological Heart Valves, and Transcatheter Heart Valves. The mechanical heart valves segment held the largest share about XX% in 2025, due to their durability and longer lifespan. Mechanical heart valves are made of materials such as titanium and carbon. They usually consist of two sheets and a metal ring surrounded by a fabric ring sewn to the core in place of the original valve. Mechanical valves are often the preferred choice for young people because they are less likely to need another valve surgery, mechanical valves significantly reduce the need for future surgeries. The long-term reliability of these valves has made them a trusted option for both patients and healthcare providers.
Despite advances in other valve technologies, many surgeons continue to prefer mechanical valves because of their consistent performance and low failure rate over time. Although patients with mechanical valves must take lifelong blood thinners to prevent blood clots, the benefits of avoiding multiple surgeries often exceed this requirement. This combination of durability, reliability, and reduced need for reintervention ensures that mechanical heart valves remain a leading choice in the heart valve devices market.
• More than 3 million mechanical heart valves have been implanted worldwide, the first and only type to reach this milestone.
• St. Jude Medical Masters Series Mechanical Heart Valve is one of the most widely used mechanical valves globally.
Heart Valve Devices Market Recent Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 03 September 2025 | Foldax | The company launched its TRIA biopolymer mitral valve in India in partnership with Dolphin Life Science LLP. | This introduces the first commercially available polymer heart valve globally, mitigating tissue degradation and avoiding the need for lifelong anticoagulation therapies. |
| 17 September 2025 | Genesis MedTech | The company's structural heart subsidiary received approval from China's NMPA for the J-Valve Transfemoral TAVI System to treat severe aortic regurgitation. | This approval establishes the first transfemoral TAVI system authorized in China specifically for aortic regurgitation, introducing a minimally invasive route that reduces surgical trauma. |
| 12 January 2026 | Edwards Lifesciences | The corporation officially terminated its planned $945 million acquisition of JenaValve Technology following antitrust opposition and a court injunction secured by the US FTC. | The termination preserves market competition by preventing a consolidated monopoly over transcatheter aortic valve devices undergoing clinical evaluation for aortic regurgitation in the United States. |
| 21 January 2026 | Medtronic | The medical technology leader agreed to purchase a strategic private equity stake of up to $90 million in heart valve developer Anteris Technologies. | The capital injection expands corporate footprint in the transcatheter aortic valve replacement (TAVR) sector by funding late-stage clinical evaluations of a biomimetic aortic valve. |
| 18 March 2026 | JenaValve | The company secured US FDA premarket approval for its Trilogy transcatheter heart valve system to treat symptomatic, severe aortic regurgitation. | This milestone delivers the first dedicated transcatheter treatment option for high-risk aortic regurgitation patients who lack calcification for anchoring standard TAVR devices. |
| 29 April 2026 | Medtronic | The firm obtained US FDA approval and initiated the commercial rollout of its next-generation Mosaic Neo bioprosthetic mitral valve. | The device updates surgical workflows by enabling both sternotomy and robotic, minimally invasive implantations to accommodate challenging patient anatomy in mitral valve disease. |
Heart Valve Devices Market Regional Insight
North America, particularly the United States, dominated the global heart valve devices market in 2025. This high volume of procedures reflects the strong demand for heart valve devices in the region. The U.S. market is a leader in adopting new technologies, particularly in minimally invasive procedures. The FDA approved transcatheter aortic valve replacement (TAVR) for low-risk patients in 2019, and the TAVR market now accounts for more than one-third of the total US heart surgery market. This adoption of TAVR is expected to grow continuously, with indicating that the number of TAVR procedures will reach over 190,000 per year by 2029. North America's dominance in the heart valve devices market is due to the success of leading companies such as Edwards Lifesciences and Medtronic, which pioneered TAVR devices. Their innovations have made them more popular and less dependent on traditional methods.
Approximately 2.5% of Americans, mostly older adults, suffer from heart valve disease, and about 28,000 people die from it each year in the U.S. The most common conditions include mitral regurgitation and aortic stenosis. Over 2 million people in the U.S. have a leaking heart valve, while 1.5 million are affected by aortic stenosis. As of 2021, the U.S. leads the North American aortic valve replacement devices market, with about 78,000 TAVI surgeries performed each year.
Heart Valve Devices Market Competitive Landscape
The heart valve devices market is highly competitive and fragmented with key players driving innovation and market growth. Edwards Lifesciences is leading the way with its advanced TAVI devices, which significantly assist in non-surgical heart valve replacement. Medtronic offers a wide range of heart valve solutions including TAVI and surgical valves and is expanding its market through new technology acquisition and integration. Boston Scientific offers a variety of heart valve products and focuses on expanding its market reach. Abbott Laboratories is known for its MitraClip for mitral valve repair and aims to lead through continuous innovation.
• In May 2024, Edwards Lifesciences launched the SAPIEN 3 Ultra RESILIA valve in Europe. This new transcatheter aortic valve features Edwards's advanced RESILIA tissue technology, which aims to improve durability. The valve has received CE Mark approval for use in patients with aortic stenosis or those who need replacement of a failed valve, especially for those at high risk for open surgery.
• In April 2022, Medtronic acquired Acutus Medical’s left heart access portfolio. This deal gives Medtronic exclusive rights to distribute and acquire Acutus Medical products used for accessing the left side of the heart. The acquisition includes devices like the AcQCross and AcQGuide lines, which help in safely reaching and treating the left atrium of the heart.
• On August 27, 2024, Boston Scientific received the CE Mark for its new ACURATE Prime Aortic Valve System. This latest addition to their structural heart portfolio is designed to improve upon their previous ACCURATE neo2 valve, featuring new design elements and an additional valve size to better accommodate patients with larger anatomy.
Heart Valve Devices Market Scope: Inquiry Before Buying
| Heart Valve Devices Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $ 11.87 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 11.2% | Market Size in 2032: | US $ 24.95 Bn. |
| Segments Covered: | by Product Type | Mechanical Heart Valves Biological Heart Valves Transcatheter Heart Valves |
|
| by Treatment | Valve Repair Valve Replacement |
||
| by End-User | Hospitals & Clinics Ambulatory Surgical Centers Cardiac Centers Others |
||
Heart Valve Devices Market, by region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)
Heart Valve Devices Market Key Players
1. Medtronic plc
2. Boston Scientific Corporation
3. Edwards Lifesciences
4. Abbott Cardiovascular
5. Foldax Inc.
6. Novostia SA
7. Meril Life Sciences Pvt. Ltd.
8. Corcym
9. Anteris Technologies Ltd
10. Artivion
11. Thubrikar Aortic Valve, Inc.
12. Biosensors International Group, Ltd.
13. MicroPort Scientific Corporation
14. Braile Biomedica
15. TTK Healthcare Limited
16. Colibri Heart Valve
17. CryoLife, Inc.
18. NeoVasc
19. Micro Interventional Devices Incorporated
20. XELTIS
Frequently Asked Questions:
1. Which region has the largest share in the Heart Valve Devices Market?
Ans: The North American region held the largest share in 2025.
2. What is the growth rate of the Heart Valve Devices Market?
Ans: The Heart Valve Devices Market is expected to grow at a CAGR of 11.2% during the forecast period 2026-2032.
3. What are the different segments of the Heart Valve Devices Market?
Ans. The Heart Valve Devices Market is divided by Product Type, Treatment and End User.
4. Who are the key players in the Heart Valve Devices Market?
Ans: The major key players in the Heart Valve Devices Market are Edwards Lifesciences, Medtronic, Boston Scientific, Abbott Laboratories and other prominent players.
5. What is the scope of the Heart Valve Devices Market report?
Ans: The Heart Valve Devices Market report helps with the PESTLE, PORTER, Recommendations for Investors & Leaders, and market estimation of the forecast period.